DUTCH PEERS Data Evaluate Newer-Generation DES at 3 Years
April 24, 2017—A report assessing the 3-year safety and efficacy of implanting newer-generation Resolute Integrity zotarolimus-eluting stents (ZES; Medtronic) versus Promus Element everolimus-eluting stents (EES; Boston Scientific Corporation) in the all-comers, investigator-initiated DUTCH PEERS trial was published online by Liefke C. van der Heijden, MD, et al in EuroIntervention.
The investigators concluded that the safety and efficacy of treating all-comers with newer-generation Resolute Integrity and Promus Element stents were found to be extended up to 3 years.
As summarized in EuroIntervention, the multicenter DUTCH PEERS trial randomly assigned a total of 1,811 all-comers patients to 1:1 treatment with ZES versus EES. A total of 1,293 patients (72%) were treated for complex lesions and 455 patients (25%) were treated for multiple lesions.
The primary endpoint of target vessel failure (TVF) is a composite of cardiac death, target vessel-related myocardial infarction, or target vessel revascularization. Adverse clinical events were independently adjudicated. Three-year follow-up data were obtained in 1,807 patients (99.8%, four withdrawals).
The investigators found that both the ZES and EES groups showed favorable outcomes with a similar incidence of TVF (10.7% vs 10.3%; log-rank P = .77) and the individual components thereof: cardiac death (3.2% vs 3.1%; log-rank P = .87), target vessel-related myocardial infarction (2.8% vs 2.2%; log-rank P = .44), and target vessel revascularization (6% vs 6.2%; log-rank P = .87). In addition, the incidence of definite or probable stent thrombosis was similar for patients treated with ZES versus EES (1.4% vs 1.1%; log-rank P = .66), reported the DUTCH PEERS investigators in EuroIntervention.